Anja Rogler
University of Erlangen-Nuremberg
17 Papers
66 Citations
Anja Rogler is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Bladder cancer & Genotype. The author has an hindex of 9, co-authored 17 publications.
Chat about Author
Papers
Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis.
Filip Roudnicky,Cédric Poyet,Peter J. Wild,Sarah Krampitz,Fabrizia Negrini,Reto Huggenberger,Anja Rogler,Robert Stöhr,Arndt Hartmann,Maurizio Provenzano,Vivianne I. Otto,Michael Detmar +11 more
TL;DR: It is suggested that endocan might serve as a useful biomarker to monitor disease progression and the efficacy of VEGF-A-targeting therapies in patients with bladder cancer and disrupting endOCan interaction with VEGFR-2 or VEGf-A could offer a novel rational strategy to inhibit tumor angiogenesis.
170
Methylation-dependent activation of CDX1 through NF-κB: A link from inflammation to intestinal metaplasia in the human stomach
Tilman T. Rau,Anja Rogler,Myrjam Frischauf,Andreas Jung,Peter C. Konturek,Arno Dimmler,Gerhard Faller,Bettina Sehnert,Wael El-Rifai,Wael El-Rifai,Arndt Hartmann,Reinhard E. Voll,Regine Schneider-Stock +12 more
TL;DR: These functionally interacting events drive CDX1 expression and contribute to intestinal metaplasia, epithelial dedifferentiation, and carcinogenesis in the human stomach.
30
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study
Anja Rogler,Sabine Hoja,Johannes Giedl,Arif B. Ekici,Sven Wach,Helge Taubert,Peter J. Goebell,Bernd Wullich,Michael Stöckle,Jan Lehmann,Sabrina Petsch,Arndt Hartmann,Robert Stoehr +12 more
TL;DR: MTUS1 is a tumour suppressor gene in cultured bladder cancer cells and in advanced bladder tumours and might represent one new target gene at chromosome 8p and can be used as an independent prognostic factor for advanced bladder cancer patients.
•Journal Article
Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.
Christine Spiegelberg,Johannes Giedl,Nadine T. Gaisa,Anja Rogler,Marc-Oliver Riener,Thomas Filbeck,Maximilian Burger,Petra Ruemmele,Arndt Hartmann,Robert Stoehr +9 more
TL;DR: The data demonstrate that the recently reported association between early-onset papillary carcinoma of the bladder with germ line FGFR2 p.Pro253Arg mutation could not be found in cohorts of sporadic bladder tumors, indicating that FGFR 2 gene mutations might only play a minor role in bladder carcinogenesis.
11